The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies
| Autor: | Henit Yanai, Russell D. Cohen, Dmitry Shuster, Srilaxmi Tumuluri, Emma Calabrese, Liat Mlynarsky |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-nuclear antibody Culprit Gastroenterology Cohort Studies Tertiary Care Centers Settore MED/12 Risk Factors Interquartile range Internal medicine medicine Humans Lupus Erythematosus Systemic Immunology and Allergy Tumor Necrosis Factor-alpha business.industry Incidence Incidence (epidemiology) Hazard ratio Antibodies Monoclonal Hydroxychloroquine Inflammatory Bowel Diseases Prognosis Confidence interval Concomitant Female business Follow-Up Studies medicine.drug |
| Zdroj: | Inflammatory Bowel Diseases. 19:2778-2786 |
| ISSN: | 1078-0998 |
| Popis: | Background The incidence of lupus-like reactions (LLRs) in patients with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor (ATNF) has not been well defined. We aimed to characterize the features and predictors associated with LLR. Methods We studied a cohort of adult patients with IBD treated with ATNF by a single specialist during 2009. Patients with LLR were characterized and compared with those without LLR for possible predictors. Results Twenty of 289 patients (6.9%) had LLR (19.9 cases per 1000 patient-years). Female gender and IBD-unclassified were more prevalent in the LLR group (85% versus 54%, P = 0.009; and 15% versus 2.2%, P = 0.018, respectively), with a hazard ratio of 3.89 (95% confidence interval = 1.12-13.55; P = 0.033) and 7.38 (95% confidence interval = 1.93-28.23; P = 0.003), respectively. ATNF duration was shorter in the LLR group (median, 1 year [interquartile range, 0-3] versus 3 years [interquartile range, 1-6.5], P = 0.005). Arthropathy was universal, followed by fatigue and dermatitis (30% each). Antinuclear antibodies were universally positive, and 16 of 20 had anti-double-stranded DNA. ATNF was discontinued in all; 8 patients required corticosteroids and 1 required hydroxychloroquine followed by complete clinical resolution (mean 7.9 ± 5.9 months). Antinuclear antibodies reverted or normalized in 7 of 16 patients (44%). Fourteen patients (70%) were switched to a second ATNF, 2 with concomitant immunomodulators, and 12 as monotherapy. One patient on ATNF monotherapy developed a second LLR and was successfully switched to a third ATNF. Conclusion LLRs secondary to ATNFs are more frequent than previously reported, more common in women and IBD-unclassified. It is reversible with cessation of the culprit agent and steroids. Switching to an alternative ATNF rarely results in recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|